As expected, KRAS-mutant cancer cell lines were more sensitive to a commercially available MEK inhibitor, trametinib, than were KRAS wild-type cancer cell lines based on screening data from The Genomics of Drug Sensitivity in Cancer Project (GDSC) (Fig. 4A, Supplementary Table 8). This evidence concerns the gene MAP2K7 and cancer.